Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moleculin Biotech (MBRX) Common Equity (2016 - 2025)

Moleculin Biotech's Common Equity history spans 10 years, with the latest figure at $15.0 million for Q4 2025.

  • Quarterly results put Common Equity at $15.0 million for Q4 2025, up 33.89% from a year ago — trailing twelve months through Dec 2025 was $15.0 million (up 33.89% YoY), and the annual figure for FY2025 was $15.0 million, up 33.89%.
  • Common Equity for Q4 2025 was $15.0 million at Moleculin Biotech, up from -$26.9 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $88.5 million in Q1 2021 to a low of -$26.9 million in Q3 2025.
  • The 5-year median for Common Equity is $37.7 million (2023), against an average of $40.3 million.
  • The sharpest move saw Common Equity soared 478.84% in 2021, then tumbled 254.61% in 2025.
  • Year by year, Common Equity stood at $79.0 million in 2021, then tumbled by 33.93% to $52.2 million in 2022, then plummeted by 40.74% to $30.9 million in 2023, then tumbled by 63.76% to $11.2 million in 2024, then soared by 33.89% to $15.0 million in 2025.
  • According to Business Quant data, Common Equity over the past three periods came in at $15.0 million, -$26.9 million, and -$3.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.